-
1
Glioblastoma (GBM) has a median overall survival of 15–20 months with standard treatment, and 8–9 months after recurrence.
-
2
Current GBM treatment focuses on prolonging survival and quality of life through surgery, radiation, and temozolomide.
-
3
Early prognostic discussions should include incurability, life expectancy, and impending cognitive decline to aid patient decision-making.
-
4
There are no specific guidelines for prognostic disclosure in neuro-oncology, leading to inconsistent communication of prognosis.
-
5
A proposed framework suggests staged disclosure of prognostic information, starting with incurability and cognitive decline at the first visit.
